Is Bio-Techne Corporation (TECH) overvalued or undervalued?

At a recent price of $72.30, Bio-Techne Corporation (TECH) sits above every lens we ran: our valuation lenses put the business somewhere between $5.18 and $52.47 per share, and they disagree too widely for us to state a single fair value. We publish the range rather than a midpoint because a number that precise would claim more than the methods can support. This is an educational model, not a price target or a recommendation.

The valuation discounts Bio-Techne Corporation's projected free cash flows at a weighted-average cost of capital (WACC) of 10.6%, with a long-run terminal growth rate of 2.5%. About 69% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.

Running the DCF in reverse — solving for the growth the current price already assumes — TECH would need sustained revenue growth of more than 25%/yr to justify today's price, against the roughly 2.7% average our base case assumes. We don't quote a precise figure here, because past about 25% a year the reverse-DCF stops being informative: it solves for revenue growth alone, holding margins, capital intensity and the forecast horizon fixed, so a price well above our fair value has nowhere to go but growth. The honest reading is that the price implies growth this model can't reconcile — not that we forecast it.

Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, TECH's modeled DCF value ranges from about $3.81 to $7.73 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.

How to read this page: the DCF fair value is what Bio-Techne Corporation would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of TECH's intrinsic value. Figures update as new filings and prices come in.